Mx1-cre or Yy1f/f
Mx1-cre bone marrow was mixed with CD45.1+ bone marrow competitor cells in a 1:1 or 9:1 ratio and transplanted into lethally irradiated CD45.1+ recipients. Four weeks after transplantation, recipient mice received 5 doses of pI-pC to delete the endogenous YY1.
(A) Lineage evaluations of donor-derived contribution in primary total peripheral blood cell, myeloid, T cells, and B cells at 4, 8, 12, and 16 weeks post BMTs.
(B) Donor-derived contribution in primary total bone marrow, spleen, and peripheral blood cells.
(C) Donor-derived contribution in primary bone marrow LSK, LT-HSC, ST-HSC, MPP, and MP.
(D) Donor-derived contribution in secondary total peripheral blood, myeloid, T and B cell.
(E) Donor-derived contribution in secondary total bone marrow, spleen, peripheral blood cells, bone marrow LSK, LT-HSC, ST-HSC, MPP, and MP. N represents the number of mice; graphs show means ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001.